A. T. Hill
About
In The Last Decade
A. T. Hill
18 papers receiving 906 citations
Peers
Comparison fields: 5 of 76
- Epidemiology 474
- Pulmonary and Respiratory Medicine 392
- Emergency Medicine 242
- Physiology 155
- Critical Care and Intensive Care Medicine 143
Countries citing papers authored by A. T. Hill
This map shows the geographic impact of A. T. Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. T. Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. T. Hill more than expected).
Fields of papers citing papers by A. T. Hill
This network shows the impact of papers produced by A. T. Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. T. Hill. The network helps show where A. T. Hill may publish in the future.
Co-authorship network of co-authors of A. T. Hill
This figure shows the co-authorship network connecting the top 25 collaborators of A. T. Hill. A scholar is included among the top collaborators of A. T. Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. T. Hill. A. T. Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients | 1 |
| 3 | Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) | 0 |
| 4 | 9 | |
| 5 | 12 | |
| 6 | 4 | |
| 7 | 26 | |
| 8 | 84 | |
| 9 | 39 | |
| 10 | 37 | |
| 11 | 248 | |
| 12 | 2 | |
| 13 | 66 | |
| 14 | 134 | |
| 15 | 173 | |
| 16 | 2 | |
| 17 | 20 | |
| 18 | 40 | |
| 19 | 38 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.